Hyloris Pharmaceuticals SA

ENXTBR:HYL Stock Report

Market Cap: €140.0m

Hyloris Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -18.1%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 52.9% per year.

Key information

-18.1%

Earnings growth rate

-2.7%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate52.9%
Return on equity-39.4%
Net Margin-365.0%
Next Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Dec 28
Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Mar 08
Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Revenue & Expenses Breakdown

How Hyloris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTBR:HYL Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 234-15614
30 Sep 233-14513
30 Jun 233-12512
31 Mar 233-12411
31 Dec 222-12410
30 Sep 223-1039
30 Jun 223-838
31 Mar 223-1037
31 Dec 213-1235
30 Sep 212-1224
30 Jun 211-1213
31 Mar 211-1023
31 Dec 200-723
30 Sep 200-832
30 Jun 200-832
31 Mar 200-612
31 Dec 190-511
31 Dec 180-615
31 Dec 170-422

Quality Earnings: HYL is currently unprofitable.

Growing Profit Margin: HYL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HYL is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.

Accelerating Growth: Unable to compare HYL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HYL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.4%).


Return on Equity

High ROE: HYL has a negative Return on Equity (-39.37%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies